VNDA: Vanda Pharmaceuticals Company Short-Term Debt

Symbol and logo of brand Vanda Pharma (VNDA)

Vanda Pharmaceuticals (VNDA) develops medications for the therapy of central nervous system disorders. The loss of patent protection for core assets is driving up legal costs, which reduces profitability, and the 0.00 market value of the asset clearly shown on this chart confirms the current trend. Successes with Fanapt and Hetlioz, along with measures to prevent a hostile takeover of the business, are creating positive momentum.

VNDA (Vanda Pharma) Company Short-Term Debts history from 07/04/2022 to 10/30/2026

Comprehensive metric breakdowns and analytics for Vanda (VNDA)

- current quotes and average value forecast:
Price Chart Vanda Pharmaceuticals Inc.|VNDA - Fair Value Consensus
- market capitalization information:
Market Value Vanda Pharmaceuticals Inc.|VNDA - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Vanda Pharmaceuticals|VNDA - Book Capitalization|Market Cap to Net Assets Ratio vandapharma.com|VNDA - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Vanda Pharmaceuticals|VNDA - Long-Term Liabilities to Equity|Short-Term Debt to Equity Vanda Pharmaceuticals|VNDA - Company Total Debt Obligations|Debt to Book Value Vanda Pharmaceuticals Inc.|VNDA - Long-Term Debt|Company Short-Term Debts Vanda Pharmaceuticals|Quick Ratio vandapharma.com
- net income and valuation multiples indicators:
VNDA - Final Profit
Fundamental company analysis:Vanda Pharmaceuticals Inc. - VNDA
Mass-produced product of Vanda Pharmaceuticals

Analyzing the resilience of Vanda Pharmaceuticals (VNDA) to market shocks requires an assessment of its liquidity. High physician confidence in its schizophrenia medications ensures a stable cash flow. The book value of short-term debt illustrates obligations maturing within one year. This metric measures the company's ability to service current loans without raising emergency capital. A low level of this indicator confirms the issuer's financial reliability.

Main competitors

ALKS - Company Short-Term Debt|Company Short-Term Loans and Borrowings AVDL (Avadel Pharmaceuticals PLC)|atai Life Sciences Corp (ATAI) - Company Short-Term Debt|Company Current Liabilities GH Research Group|MNMD (Mind Medicine) - Company Short-Term Debts|Company Short-Term Debts compasspathways.com|Company Current Liabilities LBRX (LB Pharmaceuticals)|DRUG (Bright Minds Bio) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Cybin CYBN|ANRO (Alto Neuroscience Corp) - Current Liabilities|NRXP - Company Short-Term Debt|Short-Term Debt Volume Cingulate Inc. CING|SILO (Silo Pharma) - Company Current Liabilities|Short-Term Debt China Pharma Holdings, Inc. (CPHI)|CMND (Clearmind Medicine Inc.) - Company Short-Term Debts|Company Current Liabilities Psyence Bio (PBM)|Company Short-Term Debts SPRC|SEEL (seelostherapeutics.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Virpax Pharmaceuticals, Inc. VRPX|Karuna Therapeutics Inc (KRTX) - Short-Term Debt